Related Experiment Video
Updated: Jun 5, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Use of Bevacizumab for neurological complications during initial treatment of malignant gliomas
I Arratibel-Echarren1, K Albright, J Dalmau
1Neurology Department, Neuro-Oncology Division, University of Pennsylvania, Philadelphia, USA.
Introduction:
High grade gliomas are the most common primary malignant brain tumours. Treatment with chemoradiation and adjuvant chemotherapy with Temozolomide may prolong survival but some patients develop complications during or soon after therapy due to radiation necrosis, oedema or tumour progression.
Patients:
We report the use of Bevacizumab in four patients with newly diagnosed high grade gliomas who developed cerebral oedema due to tumour progression or radiation necrosis that did not respond to corticosteroids, and who were not candidates for surgical debulking.
Outcomes:
All four patients had a rapid response to treatment with bevacizumab, tolerating a decrease of the dose of corticosteroids, and were able to continue their standard therapy.
Conclusions:
Bevacizumab is effective in controlling some of the neurological complications from oedema, radiation necrosis, or rapid tumour progression during the initial treatment of malignant gliomas.
